Constellation Pharmaceuticals (Cambridge, MA) development-stage biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epgenetic function, closed a $32M Series A financing. Participants include Third Rock Ventures, Column Group, and Venrock